A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.

The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-07799933) administered as a single agent and in combination with other study medicines in people with solid tumors. This study is seeking participants who have an advanced solid tumor with a certain type of abnormal gene called "BRAF" and available treatments are no longer effective in controlling their cancer. All participants in this study will receive PF-07799933. PF-07799933 comes as a tablet to take by mouth, 2 times a day. Depending on the part of the study, participants may als

Trial Details

NCT ID

NCT05355701

Phase

PHASE1

Sponsor

Pfizer

Status

RECRUITING

Cancer Type

Non-Small Cell (NSCLC) Lung Cancer

Interventions

PF-07799933
binimetinib
cetuximab
midazolam
fluorouracil
leucovorin

Locations (sample)

Fayetteville, Arkansas, United States|36.06258,-94.15743
Rogers, Arkansas, United States|36.33202,-94.11854
Springdale, Arkansas, United States|36.18674,-94.12881
Aurora, Colorado, United States|39.72943,-104.83192
Aurora, Colorado, United States|39.72943,-104.83192

Key Eligibility Criteria

Diagnosis of advanced/metastatic solid tumor including primary brain tumor.
Qualifying BRAF alteration (V600 or non-V600 Class II/Class III BRAF alteration), in tumor tissue and/or blood (ie circulating tumor deoxyribonucle…
Disease progressed during/following last prior treatment and no satisfactory alternative treatment options (Part 1, Part 2 (doublet), and Part 3 (c…
Tumor specific cohorts (melanoma, colorectal cancer) must have received specific prior approved therapies

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →